source
- AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survivalAbbVie announced that its bispecific antibody etentamig achieved the primary endpoint in a Phase 3 trial for patients with multiple myeloma who have progressed after two or more prior therapies. Th…
- FDA lifts clozapine monitoring requirements, easing use for children with schizophreniaThe Food and Drug Administration on Feb. 24, 2025 eliminated the long‑standing monitoring program that has governed clozapine for more than three decades. The change removes the extensive paperwork…